Sio Capital Management, LLC Neu Base Therapeutics, Inc. Transaction History

Sio Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.41 - $1.3 $265,271 - $841,105	-647,004 Reduced 71.38%	259,441 $102,000
Q3 2021 Nov 15, 2021	BUY	$3.27 - $4.76 $123,429 - $179,670	37,746 Added 4.35%	906,445 $3.27 Million
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $2.2 Million - $3.49 Million	475,000 Added 120.65%	868,699 $4.16 Million
Q1 2021 May 14, 2021	BUY	$6.92 - $12.36 $692,000 - $1.24 Million	100,000 Added 34.05%	393,699 $2.91 Million
Q4 2020 Feb 16, 2021	SELL	$6.92 - $9.25 $73,884 - $98,762	-10,677 Reduced 3.51%	293,699 $2.05 Million
Q3 2020 Nov 16, 2020	BUY	$7.25 - $9.71 $906,047 - $1.21 Million	124,972 Added 69.66%	304,376 $2.31 Million
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $1.2 Million - $2.06 Million	179,404 New	179,404 $1.58 Million

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Sio Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sio Capital Management, LLC with notifications on news.